A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
Authors: Zagni Emanuela , Bianchi Luca , Fabbrocini Gabriella , Corrao Salvatore , Offidani Annamaria , Stingeni Luca , Costanzo Antonio , Pellacani Giovanni , Peris Ketty , Bardazzi Federico , Argenziano Giuseppe , Ruffolo Silvana , Dapavo Paolo , Carrera Carlo , Fargnoli Maria Concetta , Parodi Aurora , Romanelli Marco , Malagoli Piergiorgio , Talamonti Marina , Megna Matteo , Raspanti Massimo , Paolinelli Matteo , Hansel Katharina , Narcisi Alessandra , Conti Andrea , De Simone Clara , Chessa Marco Adriano , De Rosa Alina , Provenzano Eugenio , Ortoncelli Michela , Moltrasio Chiara , Fidanza Rosaria , Burlando Martina , Tonini Annalisa , Gaiani Francesca Maria , Simoni Lucia , Zullo Alessandro , Fiocchi Martina , Colombo Delia 
Published: September 2021

AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised overall direct costs of moderate-to-severe plaque psoriasis management, the annualised cost of biologic drugs and the cost per responder in the Italian National Health System perspective were assessed. More specifically, the cost per response and cost per sustained response of the most prescribed biologic therapies for the treatment of moderate-to-severe plaque psoriasis within the CANOVA study were assessed using the Psoriasis Area Severity Index (PASI) at several score levels (75, 90 and 100%).ResultsThe most frequently used biologic therapies for plaque psoriasis were secukinumab, ustekinumab, adalimumab originator, and ixekizumab. Cost of biologics was the driver of expenditure, accounting for about 98% of total costs. Adalimumab originator was the biologic with the lowest cost per responder ratio (range: €7848 - €31,378), followed by secukinumab (range: €9015 - €33,419). Ustekinumab (range: €11,689 – €39,280) and ixekizumab (range: €11,092 – €34,289) ranked respectively third and fourth, in terms of cost-effectiveness ratio. As concerns the cost per sustained response analysis, secukinumab showed the lowest value observed (€21,375) over the other options, because of its high response rate (86% vs. 60–80%), which was achieved early in time.ConclusionBiologic therapy is a valuable asset for the treatment of moderate-to-severe plaque psoriasis. Concomitant assessment of treatment costs against the expected therapeutic response over time can provide physicians and payers additional insights which can complement the traditional risk-benefit profile assessment and drive treatment decisions.